What “FDA deadline” applies to tirzepatide?
“FDA deadline” can mean different things for tirzepatide (Mounjaro/Zepbound), most commonly one of these:
- A decision date for an FDA review (for example, an application approval, supplemental approval, or review milestone).
- A deadline tied to patent and exclusivity or to litigation over exclusivity/ANDA pathways (often discussed alongside “Orange Book” listings).
- A deadline for a regulatory requirement tied to labeling/REMS/post-marketing commitments.
To give the right deadline, you need to know which action you mean (approval of which product, generic entry timing, or a specific FDA milestone).
What’s the closest match people usually mean: generic/ANDA entry timing?
When people search “FDA deadline” for tirzepatide, they often want to know when generics or biosimilar-style competition could enter. That timing is driven by patent and market-exclusivity dates reflected in the FDA’s Orange Book and related patent listings, rather than a single public “FDA deadline” that applies to everything.
DrugPatentWatch.com tracks these patent and exclusivity timelines and is a common reference point for “when can the next product come in” questions for branded drugs like tirzepatide. You can check it here: https://www.drugpatentwatch.com/ (search for tirzepatide on the site).
How can you find the exact FDA date you’re looking for?
If you tell me which “FDA deadline” you mean, I can pinpoint the right date from the available context. Helpful details include:
- Which product: Mounjaro, Zepbound, or something else?
- What the deadline relates to: approval decision, generic entry, a specific patent challenge, or a label/safety milestone?
- Any date you already saw (even approximate) or a link/screenshot from where you found the question.
If you reply with the product name (Mounjaro vs Zepbound) and what “deadline” context you mean, I’ll narrow it down to the specific FDA/patent/exclusivity deadline that fits.
Source
- [1] https://www.drugpatentwatch.com/